FDA issues draft guidance on marketing submissions for AI-enabled medical devices
The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.
Related News Articles
Headline
The AHA Center for Health Innovation released a new report to guide hospital and health system executives on using artificial intelligence and AI-powered…
Headline
The Department of Health and Human Services Jan. 10 released its Strategic Plan for the Use of Artificial Intelligence in Health, Human Services, and Public…
Headline
The Food and Drug Administration yesterday released recommendations for streamlining the approval process for medical devices that use artificial intelligence…
Headline
Chris DeRienzo, M.D., AHA chief physician executive and senior vice president, participated Sept. 17 in a Newsweek event on physician burnout and how…
Headline
The Coalition to Strengthen America’s Healthcare Sept. 18 sponsored an event with Politico in Washington, D.C. to discuss innovations in telehealth, artificial…
Headline
The Department of Health and Human Services Sept. 17 announced it has awarded a total of $2 million to two recipients to create tools to improve care delivery…